TransMedics Group (NASDAQ:TMDX) Director Buys 1,336 Shares of Stock

TransMedics Group, Inc. (NASDAQ:TMDX) Director David Weill purchased 1,336 shares of the firm’s stock in a transaction that occurred on Friday, September 11th. The shares were acquired at an average cost of $81.63 per share, with a total value of $109,057.68. Following the completion of the transaction, the director owned 16,392 shares in the company, valued at $1,338,078.96. This trade represents a 8.87% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website.

TransMedics Group Stock Up 4.5%

NASDAQ:TMDX traded up $3.68 during mid-day trading on Monday, hitting $85.86. The company had a trading volume of 942,830 shares, compared to its average volume of 1,033,064. The business has a fifty day simple moving average of $82.00 and a 200-day simple moving average of $90.26. The firm has a market capitalization of $2.97 billion, a price-to-earnings ratio of 22.07, a PEG ratio of 1.13 and a beta of 1.90. TransMedics Group, Inc. has a 1 year low of $60.10 and a 1 year high of $156.00. The company has a current ratio of 6.62, a quick ratio of 6.07 and a debt-to-equity ratio of 1.62.

TransMedics Group (NASDAQ:TMDX) last issued its earnings results on Tuesday, August 4th. The company reported $0.44 earnings per share for the quarter, missing the consensus estimate of $0.50 by ($0.06). TransMedics Group had a return on equity of 15.88% and a net margin of 22.69%.The company had revenue of $189.95 million during the quarter, compared to analysts’ expectations of $184.00 million. During the same period in the previous year, the company earned $0.92 EPS. TransMedics Group’s quarterly revenue was up 20.7% on a year-over-year basis. Equities analysts forecast that TransMedics Group, Inc. will post 1.46 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have issued reports on the stock. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $124.00 price objective on shares of TransMedics Group in a research report on Tuesday, June 30th. Needham & Company LLC restated a “buy” rating on shares of TransMedics Group in a research note on Friday. Weiss Ratings raised shares of TransMedics Group from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, August 31st. UBS Group dropped their price target on shares of TransMedics Group from $80.00 to $77.00 and set a “neutral” rating on the stock in a research note on Wednesday, August 5th. Finally, Stifel Nicolaus upped their price objective on shares of TransMedics Group from $75.00 to $80.00 and gave the company a “hold” rating in a research report on Thursday, June 18th. Six analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, TransMedics Group currently has an average rating of “Hold” and a consensus target price of $124.18.

Institutional Trading of TransMedics Group

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Silvant Capital Management LLC acquired a new position in TransMedics Group in the second quarter worth approximately $26,000. North Star Investment Management Corp. acquired a new stake in shares of TransMedics Group during the 1st quarter valued at $30,000. Ascentis Independent Advisors bought a new stake in shares of TransMedics Group during the 1st quarter worth $30,000. State of Wyoming acquired a new position in shares of TransMedics Group in the 2nd quarter worth $31,000. Finally, Ancora Advisors LLC acquired a new position in shares of TransMedics Group in the 2nd quarter worth $33,000. 99.67% of the stock is owned by institutional investors and hedge funds.

About TransMedics Group

TransMedics Group, Inc is a medical technology company focused on improving organ transplantation. The company develops and commercializes organ preservation and transport technologies designed to maintain donor organs in a functioning condition outside the body, potentially supporting evaluation and extending the time available for transplantation.

Its primary product is the Organ Care System (OCS), a portable perfusion platform that circulates oxygenated, nutrient-enriched fluid through donor organs.